Thompson Davis & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Thompson Davis & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$313K	Hold	10,400	–	–	0.21%	80
2025 Q4	$325K	Hold	10,400	–	–	0.19%	91
2025 Q3	$210K	Buy	+10,400	New	+$183K	0.13%	119
2017 Q1	–	Sell	-271	Closed	-$10K	–	1230
2016 Q4	$10K	Hold	271	–	–	0.02%	707
2016 Q3	$12K	Hold	271	–	–	0.02%	626
2016 Q2	$14K	Hold	271	–	–	0.02%	564
2016 Q1	$15K	Buy	271 +34	+14%	+$2K	0.02%	542
2015 Q4	$16K	Sell	237 -112	-32%	-$6.92K	0.02%	532
2015 Q3	$20K	Buy	349 +47	+16%	+$3.05K	0.03%	469
2015 Q2	$18K	Hold	302	–	–	0.02%	575
2015 Q1	$19K	Sell	302 -121	-29%	-$7.04K	0.02%	545
2014 Q4	$24K	Buy	423 +61	+17%	+$3.4K	0.03%	466
2014 Q3	$19K	Buy	+362	New	+$19.2K	0.02%	483

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thompson Davis & Co's TEVA Position: Q1 2026 in Review

Thompson Davis & Co held its Teva Pharmaceuticals (TEVA) position steady in Q1 2026 at 10,400 shares worth $313K. The position accounts for 0.21% of the portfolio, ranked #80.

Thompson Davis & Co first reported a position in TEVA in Q3 2014 and has held it in 13 quarters since. The position peaked at $325K in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Thompson Davis & Co held 10,400 shares of Teva Pharmaceuticals worth $313K as of Q1 2026.
Thompson Davis & Co left its Teva Pharmaceuticals share count unchanged in Q1 2026.
Teva Pharmaceuticals made up 0.21% of Thompson Davis & Co's portfolio in Q1 2026, its #80 holding.
Thompson Davis & Co first reported a position in Teva Pharmaceuticals in Q3 2014 and has held it in 13 quarters since.
Thompson Davis & Co's Teva Pharmaceuticals position peaked at $325K in Q4 2025.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Thompson Davis & Co's 13F filing for Q1 2026, filed 16 Apr 2026.